Investors

CNSX: MEND | OTC: MNNDF | FRA: 8TV

Investor photo
Investor photo

Nurosene will revolutionize how consumers approach their performance and wellness needs.

The Opportunity

1.5T Market

Health + Wellness

$10.5B by 2025

Performance

$14B by 2025

Self-Improvement

264M Affected Globally

Mental Health

The Nuro Solution

Nuro – The world’s first app that understands the underlying brain biology by using our proprietary Virtual Neural Scan.

Nuro – Will make recommendations that improve specific core neural networks and improve brain coherence.

Nurosene
– Will own the world’s most advanced brain based population data set.

Nurosene – Will drive this data through our advanced AI platform – NetraMark’s NetraAI.

NetraAI – Will identify precision drugs and nutraceuticals and we will hold a carried interest in these candidates.

Corporate Directory

Nurosene

[Head Office]

1655 Dupont St. #Suite 101

Toronto, ON M6P 3S9

investors@nurosene.com

Fasken Martineau DuMoulin LLP

[Legal]

2400 - 333 Bay St.

Toronto, ON M5H 2T6

416.366.8381

MNP LLP

[Auditors]

111 Richmond St. W Suite 300

Toronto, ON M5H 2G4

416.596.1711

Odyssey Trust

[Transfer Agent]

United Kingdom Building 323

409 Granville Street

Vancouver, BC V6C 1T2

1.833.392.7716